Nintedanib in PF-ILD
Research type
Research Study
Full title
An open-label extension trial of the long-term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
IRAS ID
252018
Contact name
Simon Daniels
Contact email
Sponsor organisation
Boehringer Ingelheim
Eudract number
2018-000525-32
Duration of Study in the UK
3 years, 3 months, 15 days
Research summary
A phase III extension study investigating long term treatment with nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have completed (and did not prematurely discontinue trial medication in) the phase III parent trial, 1199.247 (INBUILD). We aim to explore the long-term safety of nintedanib in patients with progressive scarring of the lungs.
REC name
East Midlands - Leicester Central Research Ethics Committee
REC reference
18/EM/0365
Date of REC Opinion
14 Jan 2019
REC opinion
Further Information Favourable Opinion